Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17069780 | 0.83 | HCRTR1 (0.46) | HCRTR1HCRTR2 | |
| SCHEMBL16025401 | 0.83 | HCRTR1 (0.49) | HCRTR1HCRTR2 | |
| SCHEMBL27870874 | 0.82 | HCRTR1 (0.50) | HCRTR1HCRTR2 | |
| SCHEMBL1586205 | 0.81 | HCRTR1 (0.49) | HCRTR1HCRTR2 | |
| SCHEMBL1672211 | 0.81 | HCRTR1 (0.49) | HCRTR1HCRTR2 | |
| SCHEMBL29597179 | 0.81 | HCRTR1 (0.49) | HCRTR1HCRTR2 | |
| Iodomethane SCHEMBL31482883 | 0.80 | HCRTR1 (0.48) | HCRTR1HCRTR2 | |
| SCHEMBL16666175 | 0.80 | HCRTR1 (0.48) | HCRTR1HCRTR2 | |
| SCHEMBL18195531 | 0.79 | HCRTR2 (0.48) | HCRTR1HCRTR2 | |
| SCHEMBL18594654 | 0.79 | HCRTR1 (0.46) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9975876-B2 | 2-pyridyloxy-3-ester-4-ether orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-05-22 | — | — | US | disclosed |
| US-9975876-B2 | 2-pyridyloxy-3-ester-4-ether orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-05-22 | — | — | US | disclosed |
| US-9745284-B2 | 2-pyridyloxy-4-ether orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745284-B2 | 2-pyridyloxy-4-ether orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9617246-B2 | Thioether-piperidinyl orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617246-B2 | Thioether-piperidinyl orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9586934-B2 | 2-pyridyloxy-4-methyl orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586950-B2 | 2-pyridyloxy-3-ester-4-nitrile orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586950-B2 | 2-pyridyloxy-3-ester-4-nitrile orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586934-B2 | 2-pyridyloxy-4-methyl orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160368898-A1 | 2-PYRIDYLOXY-4-METHYL OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-12-22 | — | — | US | disclosed |
| US-20160318899-A1 | THIOETHER-PIPERIDINYL OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160304490-A1 | 2-PYRIDYLOXY-3-ESTER-4-ETHER OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-10-20 | — | — | US | disclosed |
| US-20160016935-A1 | 2-PYRIDYLOXY-4-ETHER OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-01-21 | — | — | US | disclosed |
| US-20150252033-A1 | 2-PYRIDYLOXY-3-ESTER-4-NITRILE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252033-A1 | 2-PYRIDYLOXY-3-ESTER-4-NITRILE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NTSR2 | HCRTR1 2/4885HCRTR2 1/4885 |
| US-20160304490-A1 | 2-PYRIDYLOXY-3-ESTER-4-ETHER OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY4R | HCRTR1 2/4885HCRTR2 1/4885 |
| US-20160318899-A1 | THIOETHER-PIPERIDINYL OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | HCRTR1 2/4885HCRTR2 1/4885 |
| US-20160368898-A1 | 2-PYRIDYLOXY-4-METHYL OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | HCRTR1 2/4885HCRTR2 1/4885 |
| US-20160016935-A1 | 2-PYRIDYLOXY-4-ETHER OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | HCRTR1 2/4885HCRTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.